0001209191-21-012111.txt : 20210218
0001209191-21-012111.hdr.sgml : 20210218
20210218185948
ACCESSION NUMBER: 0001209191-21-012111
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200218
FILED AS OF DATE: 20210218
DATE AS OF CHANGE: 20210218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Glenn Gregory M
CENTRAL INDEX KEY: 0001342823
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26770
FILM NUMBER: 21651305
MAIL ADDRESS:
STREET 1: 20 FIRSTFIELD ROAD, #250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVAVAX INC
CENTRAL INDEX KEY: 0001000694
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 222816046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-268-2000
MAIL ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-18
0
0001000694
NOVAVAX INC
NVAX
0001342823
Glenn Gregory M
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD
GAITHERSBURG
MD
20878
0
1
0
0
President, R&D
Common Stock
2021-02-18
4
S
0
80
264.092
D
5165
D
Common Stock
2021-02-18
4
S
0
361
265.5246
D
4804
D
Common Stock
2021-02-18
4
S
0
128
266.6763
D
4676
D
Common Stock
2021-02-18
4
S
0
268
268.1904
D
4408
D
Common Stock
2021-02-18
4
S
0
678
269.2269
D
3730
D
Common Stock
2021-02-18
4
S
0
319
269.9346
D
3411
D
Common Stock
2021-02-18
4
S
0
110
271.1578
D
3301
D
Common Stock
2021-02-18
4
S
0
205
272.4283
D
3096
D
Common Stock
2021-02-18
4
S
0
67
273.6079
D
3029
D
Common Stock
2021-02-18
4
S
0
48
274.63
D
2981
D
Common Stock
2021-02-18
4
S
0
32
276.23
D
2949
D
Common Stock
2021-02-18
4
S
0
65
278.2705
D
2884
D
Common Stock
2021-02-18
4
S
0
73
279.2022
D
2811
D
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.90 to $264.22,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.08 to $266.02,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.44 to $266.96,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.63 to $268.59,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.69 to $269.68,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.75 to $270.24,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.82 to $271.61,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.90 to $272.77,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.54 to $273.67,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.91 to $278.62,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.00 to $279.41,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.
/s/ John A. Herrmann III, Attorney-in-Fact
2021-02-18